RecruitingNCT07131956
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy (ImmunBioProBrachy)
Sponsor
University of Erlangen-Nürnberg Medical School
Enrollment
200 participants
Start Date
Dec 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria8
- Primary treatment with I-125 seeds or HDR-BT
- No previous treatment for prostate cancer
- Age ≥ 18 years
- HDR- or PDR-BT
- No radiation therapy within three months before salvage treatment
- Complete documentation available on previous treatment for prostate cancer
- No history of prostatectomy
- Age ≥ 18 years
Exclusion Criteria3
- Pre-existent auto-immune disease
- patients under bloodthinning medication
- substance abuse
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07131956
Related Trials
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT073320007 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
SpaceOAR Post-Market Registry Study
NCT073006318 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial
NCT071306821 location